IL129286A0 - Reshaped human anti-HM 1.24 antibody - Google Patents

Reshaped human anti-HM 1.24 antibody

Info

Publication number
IL129286A0
IL129286A0 IL12928697A IL12928697A IL129286A0 IL 129286 A0 IL129286 A0 IL 129286A0 IL 12928697 A IL12928697 A IL 12928697A IL 12928697 A IL12928697 A IL 12928697A IL 129286 A0 IL129286 A0 IL 129286A0
Authority
IL
Israel
Prior art keywords
chain
antibody
human
reshaped human
region
Prior art date
Application number
IL12928697A
Other languages
English (en)
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL129286A0 publication Critical patent/IL129286A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL12928697A 1996-10-04 1997-10-03 Reshaped human anti-HM 1.24 antibody IL129286A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04
PCT/JP1997/003553 WO1998014580A1 (fr) 1996-10-04 1997-10-03 Anticorps anti-hm1.24 humain reconstitue

Publications (1)

Publication Number Publication Date
IL129286A0 true IL129286A0 (en) 2000-02-17

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12928697A IL129286A0 (en) 1996-10-04 1997-10-03 Reshaped human anti-HM 1.24 antibody

Country Status (19)

Country Link
US (2) US6699974B2 (cs)
EP (1) EP0960936B1 (cs)
KR (1) KR100388256B1 (cs)
CN (2) CN1271205C (cs)
AT (1) ATE512224T1 (cs)
AU (1) AU715156B2 (cs)
BR (1) BR9712488A (cs)
CA (1) CA2267072C (cs)
CZ (1) CZ296790B6 (cs)
IL (1) IL129286A0 (cs)
NO (1) NO325178B1 (cs)
PL (1) PL187642B1 (cs)
RU (1) RU2184147C2 (cs)
SK (1) SK44399A3 (cs)
TR (1) TR199900722T2 (cs)
TW (1) TW530064B (cs)
UA (1) UA76934C2 (cs)
WO (1) WO1998014580A1 (cs)
ZA (1) ZA978865B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100655979B1 (ko) 1997-02-12 2006-12-08 츄가이 세이야꾸 가부시키가이샤 임파구계 종양의 치료제
CA2282631A1 (en) * 1997-02-28 1998-09-03 Chugai Seiyaku Kabushiki Kaisha Lymphocyte activation inhibitors
KR100362974B1 (ko) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 림프구계 종양에 대한 항체의 증진제
EP1757941B1 (en) * 1998-02-25 2010-03-31 Chugai Seiyaku Kabushiki Kaisha Method for immunochemically assaying anti-hm1.24 antibody
US6602663B1 (en) 1998-09-18 2003-08-05 Chugai Seiyaku Kabushiki Kaisha Method for detection or measuring plasmocytoma cells
US6900052B1 (en) 1999-05-10 2005-05-31 Chugai Seiyaku Kabushiki Kaisha Method of culturing cells
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
AU2001246846A1 (en) * 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
WO2002057316A1 (fr) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Nouvel anticorps monoclonal
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
AU2002252456A1 (en) * 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
WO2002084290A1 (fr) 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
DK1475101T3 (da) * 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
EP1561756B1 (en) 2002-09-11 2015-12-23 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
WO2005014651A1 (ja) 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
KR101364858B1 (ko) * 2003-11-05 2014-02-19 로슈 글리카트 아게 증가된 fc 수용체 결합 친화성 및 효과기 기능을 가진 cd20 항체
DK1716181T3 (da) * 2004-02-19 2010-03-01 Genentech Inc CDR-reparerede antistoffer
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
AR055137A1 (es) * 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
HUE049825T2 (hu) 2009-09-03 2020-10-28 Merck Sharp & Dohme Anti-GITR antitestek
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
EP2750784A1 (en) 2011-09-01 2014-07-09 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
AU2014370873B2 (en) 2013-12-27 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク. 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
JP2021521110A (ja) 2018-04-06 2021-08-26 エータイアー ファーマ, インコーポレイテッド 抗nrp2抗体を含む組成物及び方法
TWI840360B (zh) 2018-05-21 2024-05-01 日商中外製藥股份有限公司 密封於玻璃容器之凍結乾燥的製劑、套組、製造凍結乾燥製劑的方法、防止或減低凍結乾燥製劑的玻璃容器成霧的方法、及容器內面經過硫酸銨處理或vist處理之玻璃容器
JP6955098B2 (ja) 2018-05-28 2021-10-27 中外製薬株式会社 充填ノズル
CN114746120B (zh) * 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
KR20240082388A (ko) 2021-10-08 2024-06-10 추가이 세이야쿠 가부시키가이샤 프리필드 시린지 제제의 조제 방법
CN119486774A (zh) 2022-04-26 2025-02-18 中外制药株式会社 含有药物制剂的内置过滤器的注射器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
TW205553B (cs) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
KR100655979B1 (ko) * 1997-02-12 2006-12-08 츄가이 세이야꾸 가부시키가이샤 임파구계 종양의 치료제
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
ATE373712T1 (de) * 1997-10-03 2007-10-15 Chugai Pharmaceutical Co Ltd Natürlicher menschlicher antikörper
KR100362974B1 (ko) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 림프구계 종양에 대한 항체의 증진제
CA2492092A1 (en) * 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs

Also Published As

Publication number Publication date
BR9712488A (pt) 1999-10-19
AU715156B2 (en) 2000-01-20
EP0960936B1 (en) 2011-06-08
RU2184147C2 (ru) 2002-06-27
US20030129185A1 (en) 2003-07-10
CZ117399A3 (cs) 1999-09-15
ATE512224T1 (de) 2011-06-15
TR199900722T2 (xx) 1999-12-21
NO991591L (no) 1999-06-01
EP0960936A1 (en) 1999-12-01
EP0960936A4 (en) 2005-01-19
UA76934C2 (en) 2006-10-16
NO325178B1 (no) 2008-02-11
CA2267072A1 (en) 1998-04-09
TW530064B (en) 2003-05-01
CN1271205C (zh) 2006-08-23
CZ296790B6 (cs) 2006-06-14
US6699974B2 (en) 2004-03-02
NO991591D0 (no) 1999-03-31
PL332742A1 (en) 1999-10-11
CA2267072C (en) 2004-11-30
HK1024261A1 (en) 2000-10-05
CN1765928A (zh) 2006-05-03
US7892543B2 (en) 2011-02-22
KR100388256B1 (ko) 2003-06-19
AU4399297A (en) 1998-04-24
ZA978865B (en) 1998-04-20
KR20000048884A (ko) 2000-07-25
PL187642B1 (pl) 2004-08-31
SK44399A3 (en) 2000-05-16
CN1235639A (zh) 1999-11-17
US20030045691A1 (en) 2003-03-06
WO1998014580A1 (fr) 1998-04-09

Similar Documents

Publication Publication Date Title
ZA978865B (en) Reshaped human anti-HM 1.24 antibody.
AU2936395A (en) Reconstituted human antibody against human interleukin-8
IL138801A0 (en) Humanized antibody against human tissue factor and process for the preparation thereof
EP1020522A4 (en) NATURAL HUMAN ANTIBODY
IL189629A0 (en) Compositions containing human ctla-4 antibodies
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
EP0657486A3 (en) Fluorine-modified silicone, process for its production and cosmetics containing it.
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
WO1994011026A3 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
GR3026519T3 (en) New method of treating depression
ZA972757B (en) Porphyromonas gingivalis antigents for the diagnosis and treatment of periodontitis.
IL173988A0 (en) RESHAPED MONOCLONAL ANTIBODIES SPECIFIC FOR IgE
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
RU93035807A (ru) Способ лечения юношеского эпифизиолиса

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees